DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: Prospective studies monitoring the kinetics of CD26+ LSCs during TKI treatment have detected circulating CD26+ LSCs in 66% of CML patients in the TFR phase, although this number was significantly decreased compared with initial diagnosis [35,44].